Relevant BNF section: 11.8.2
Age-related macular degeneration (AMD), a disorder affecting older people, is the commonest cause of severe visual impairment in the UK.1 It involves degeneration of the central retina (the macula) that results in diminished capacity for detailed visual tasks, such as reading, writing and recognising faces. For most people with AMD there is no effective treatment. ▼Verteporfin* (Visudyne - Novartis Ophthalmics) was licensed last year for use in conjunction with laser activation (photodynamic therapy) for the treatment of "age-related macular degeneration in patients with predominantly classic subfoveal neovascularisation".3 Here, we review the place of this treatment.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.